生黄合剂对病毒性心肌炎小鼠的干预实验

An experiment on the interventional effects of Shenghuang reagent on mice with viral myocarditis

目的:观察生黄合剂对病毒性心肌炎小鼠的治疗作用。方法:实验于2003-10/2004-12在承德医学院中心实验室完成。生脉饮(人参:五味子:麦冬=1∶2∶1)与总黄酮按不同比例制成1∶1、1∶2合剂。将180只昆明种小鼠按分层随机方法分为6组:生脉饮治疗组、1∶1液治疗组、1∶2液治疗组、阳性药物对照组、病毒对照组、正常对照组,每组30只。生脉饮治疗组、1∶1液治疗组、1∶2液治疗组、阳性药物对照组、病毒对照组腹腔注射1000TCID50/0.1mL的柯萨奇B组病毒0.1mL,正常对照组腹腔注射RPMI1640维持液0.1mL,1h后生脉饮治疗组、1∶1液治疗组、1∶2液治疗组灌胃给药,0.2mL/10g,阳性药物对照组利巴韦林0.1mL/10g腹腔注射,正常对照组给予相同剂量的生理盐水灌胃,2次/d,持续给药10d。于第7天每组随机抽取6只小鼠摘眼球取血并分离血清,用AU640全自动生化分析仪测定心肌酶。观察生黄合剂对模型鼠的一般情况、生存率、心肌病理损害及心肌酶的影响。结果:180只小鼠均进入结果分析,中途无脱落。①各组生存率比较:生脉饮治疗组、1∶1液治疗组、1∶2液治疗组、阳性药物对照组与病毒对照组比较,差异显著(50%,79%,67%,33%,25%,χ2=40.11,P<0.005);生脉饮治疗组与1∶1液治疗组比较,差异显著(χ2=4.46,P<0.05),1∶1液治疗组和1∶2液治疗组分别与阳性药物对照组比较,差异均显著(χ2=10.24,χ2=5.33,P<0.05)。②除正常对照组外,其他各组小鼠在感染柯萨奇B组病毒后均出现不同程度的心脏病理改变。生脉饮治疗组与1∶1液治疗组小鼠的心肌病理积分低于病毒对照组(0.80±0.45,0.40±0.55,2.40±1.14,P<0.05)。各治疗组小鼠血清心肌酶明显低于病毒对照组[肌酸磷酸激酶:(16.26±2.89),(13.41±1.81),(16.90±3.42),(17.33±3.31),(25.03±3.50)mkat/L,P<0.05;肌酸磷酸激酶同工酶:(10.72±2.69),(10.41±2.03),(10.30±2.72),(15.14±2.92),(24.25±3.28)mkat/L,P<0.05],各治疗组之间比较无统计学意义。结论:实验所试药物对柯萨奇B组病毒感染鼠均有保护作用,1∶1液治疗组、1∶2液治疗组对感染鼠的保护和治疗作用要好于阳性药物利巴韦林对照组,尤其是1∶1液治疗组的保护和治疗作用最佳。

AIM： To observe the therapeutic effects of Shenghuang reagent on mice with viral myocarditis （VM）. METHODS： The experiment was conducted in the Central Laboratory of Chengde Medical College from October 2003 to December 2004. The reagent was manufactured by Shengmaiyin （ginseng： fructus schizandrae： ophiopogonis tuber=1：2：1） and total flavonoids at the ratios of 1：1 and 1：2 respectively. 180 mice of Kunming species were divided into 6 groups by random stratification： Shengmaiyin treatment group, 1：1 liquid treatment group, 1：2 liquid treatment group, positive medicine control group, virus control group and normal control group with 30 mice in each group. Mice in the Shengmaiyin treatment group, 1：1 liquid treatment group, 1：2 liquid treatment group, positive medicine control group and the virus control group were intraperitoneally injected with 0.1 mL of 1000TCID50/0.1 mL CYB, while mice in the normal control group were given intraperitoneal injection of 0.1 mL of RPMI 1640 main medium. One hour after that, mice in the Shengmaiyin treatment group, 1：1 liquid treatment group and 1：2 liquid treatment group were intragastrically administrated at 0.2 mL./10 g, and mice in the positive medicine control group were abdominally injected with 0.1 mL/10 g of ribavirin, and mice in the normal control group were given gastric perfusion of normal saline at the same dose twice a day for 10 continuous days. On the 7^th day, 6 mice were selected randomly from each group to remove their eyeballs and isolate the serum. The AU640 automatic biochemistry analyzer was used to determine the myocardial enzyme. The effects of Shengmaiyin reagent on general condition, survival rate, myocardial pathological injury and myocardial enzyme of mice were observed. RESULTS： A total of 180 mice were involved in the analysis of results, and no mouse withdrew from the study. ①Comparison in survival rate among each group： it was significantly different in the virus control group from those in the Shengmaiyin treatment group, 1：1 liquid treatment group, 1：2 liquid treatment group and positive medicine control group（50%,79%, 67%,33%,25%,χ^2=40.11 ,P 〈 0.005）, and it was obviously different between Shengmaiyin treatment group and 1：1 liquid treatment group（χ^2=4.46,P 〈 0.05）. There were remarkable differences in compared the 1：1 liquid treatment group and the 1：2 liquid treatment group with the positive medicine control group （χ^2=10.24,χ^2=5.33,P 〈 0.05）.②Except the normal control group, all the mice in the other groups showed cardiac pathological changes to different degree after being infected with CVB. The integrals of myocardial pathological in mice of the Shengmaiyin treatment group and 1：1 liquid treatment group were markedly lower than that in the virus control group （0.80±0.45,0.40±0.55,2.40±1.14,P 〈 0.05）. The serum myocardial enzymes of mice in all treatment groups were apparently lower than that in the virus control group [creatine phosphokinase： （16.26 ±2.89）, （13.41±1.81）, （16.90±3.42）, （ 17.33±3.31 ）, （25.03±3.50） mkat/L,P 〈 0.05;ereatine phosphokinase isoenzyme： （ 10.72 ±2.69）, （ 10.41 ±2.03）, （ 10.30±2.72）, （ 15.14±2.92）, （24.25±3.28） mkat/L,P 〈 0.05]. There was no statistical significance in comparison among all treatment groups.CONCLUSION： Testing drugs in the experiment have protective effects on mice infected by CVB, while the protection and treatment in the 1：1 liquid treatment group and 1：2 liquid treatment group are better than those in the positive medicine ribavirin control group, and the effects of the 1：1 liquid treatment group are the best.